[Treatment of endometriosis, Clinical trial with danazol].
21 women with endometriosis were treated with Danazol, a derivative of 17-alpha-aethinyltestosteron in an open study over a period of 6 months. 20 women had previously undergone an operation because of the spread of endometriosis and its symptoms, in no case was it possible to remove the source of the endometriosis entirely. Histological confirmation of the endometriosis was ensured in each case. The initial dose was 600 mg Danazol daily. In 17 cases the dose was reduced in the course of 6 months and in 5 cases treatment had to be stopped between the 4th and 6th month. An improvement of the symptoms arising occurred under this treatment. Side-effects, observed during the treatment with Danazol, such as acne vulgaris, seborrhoea, flushes and headaches occurred in 6 respectively 5 cases (28,6 respectively 23,8%). Very occasionally pain in the joints was reported. Almost all women put on weight. The effect of this treatment on fat- and glycometabolism, on liver- and kidney function, on blood-coagulation as well as bloodpressure was examined, no divergence from the norm was observed.
D000152:Acne Vulgaris / Q000139:chemically induced; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D001941:Breast Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D004414:Dyspareunia / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007044:Hysterectomy; D007592:Joint Diseases / Q000139:chemically induced; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011245:Pregnadienes / Q000627:therapeutic use*
D011245:Pregnadienes; D003613:Danazol
Behandlung der Endometriose Klinische Prüfung mit Danazol.